Detalhe da pesquisa
1.
Growth dynamics in naturally progressing chronic lymphocytic leukaemia.
Nature
; 570(7762): 474-479, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31142838
2.
A large fraction of trisomy 12, 17p-, and 11q- CLL cases carry unidentified microdeletions of miR-15a/16-1.
Proc Natl Acad Sci U S A
; 119(4)2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35064090
3.
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
Breast Cancer Res
; 26(1): 32, 2024 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38408999
4.
ROR1: an orphan becomes apparent.
Blood
; 140(14): 1583-1591, 2022 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35580162
5.
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Blood
; 139(12): 1794-1806, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699592
6.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood
; 139(22): 3278-3289, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196370
7.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood
; 140(8): 839-850, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35605176
8.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
J Natl Compr Canc Netw
; 22(3): 175-204, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38626800
9.
Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
Breast Cancer Res Treat
; 199(2): 281-291, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37029329
10.
Exploring the pathways to chronic lymphocytic leukemia.
Blood
; 138(10): 827-835, 2021 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34075408
11.
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Blood
; 138(10): 836-846, 2021 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34115103
12.
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
Blood
; 137(18): 2481-2494, 2021 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33171493
13.
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Future Oncol
; 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36617990
14.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med
; 380(23): 2225-2236, 2019 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166681
15.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
J Natl Compr Canc Netw
; 20(6): 622-634, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714675
16.
Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia.
Proc Natl Acad Sci U S A
; 116(48): 24252-24258, 2019 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31723042
17.
Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.
Proc Natl Acad Sci U S A
; 116(4): 1370-1377, 2019 01 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30622177
18.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 378(12): 1107-1120, 2018 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562156
19.
Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia.
Blood
; 133(25): 2651-2663, 2019 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923040
20.
Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.
Blood
; 134(13): 1084-1094, 2019 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31409670